UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 6, 2025
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 6 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Liselotte Sofie Hyveled | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Member of the Board of Directors | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction |
Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 1,407 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
1,407 shares DKK 0.00 | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | President and CEO | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction |
Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 98,702 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
98,702 shares DKK 0.00 | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | President and CEO | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 618.10 DKK | 32 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
32 shares 19,779 DKK | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | AQUIS EXCHANGE EUROPE NON DISPLAY ORDER BOOK (NDOB) | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | President and CEO | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 619.48 DKK | 1,104 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
1,104 shares 683,905 DKK | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | AQUIS EXCHANGE EUROPE | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | President and CEO | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 617.56 DKK | 978 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
978 shares 603,976 DKK | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | CBOE EUROPE - DXE PERIODIC (NL) | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | President and CEO | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 621.01 DKK | 42 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
42 shares 26,083 DKK | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | CBOE EUROPE - DXE DARK ORDER BOOK (NL) | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | President and CEO | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 618.17 DKK | 8,331 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
8,331 shares 5,149,984 DKK | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | CBOE EUROPE - DXE ORDER BOOKS (NL) | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | President and CEO | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 618.14 DKK | 1,577 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
1,577 shares 974,805 DKK | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | TURQUOISE EUROPE | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | President and CEO | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 618.88 DKK | 22,936 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
22,936 shares 14,194,575 DKK | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | NASDAQ COPENHAGEN A/S | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction |
Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 36,956 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
36,956 shares DKK 0.00 | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 614.55 | 1,852 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
1,852 shares DKK 1,138,154 | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction |
Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 27,765 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
27,765 shares DKK 0.00 | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 614.55 | 8,990 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
8,990 shares DKK 5,524,840 | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 617.00 | 12,000 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
12,000 shares DKK 7,404,000 | |||
| e) | Date of the transaction | 2025-02-06 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction |
Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 30,728 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
30,728 shares DKK 0.00 | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Martin Holst Lange | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction |
Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 30,728 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
30,728 shares DKK 0.00 | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Tania Sabroe | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction |
Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 10,561 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
10,561 shares DKK 0.00 | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Marcus Schindler | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction |
Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 30,728 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
30,728 shares DKK 0.00 | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Camilla Sylvest | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction |
Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 30,728 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
30,728 shares DKK 0.00 | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Camilla Sylvest | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 615.00 | 15,364 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
15.364 shares DKK 9,448,860 | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Henrik Ehlers Wulff | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction |
Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 32,448 shares | ||||
| d) |
Aggregated information · Aggregated volume · Price |
32,448 shares DKK 0.00 | |||
| e) | Date of the transaction | 2025-02-05 | |||
| f) | Place of the transaction | Outside a trading venue | |||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
|
Ambre James-Brown +45 3079 9289 |
Liz Skrbkova (US) +1 609 917 0632 |
| Investors: | |
|
Jacob Martin Wiborg Rode +45 3075 5956 |
David Heiberg Landsted +45 3077 6915 |
|
Sina Meyer +45 3079 6656 |
Ida Schaap Melvold +45 3077 5649 |
|
Max Ung +45 3077 6414 |
Frederik Taylor Pitter +1 609 613 0568 |
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 8 / 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 6, 2025 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen Chief Executive Officer |